Global Trazodone Hydrochloride (API) Market Research Report 2022

Trazodone, a phenylpiperazine–triazolopyridine antidepressant, was originally discovered and developed in Italy in the 1970s by Angelini research laboratories. Trazodone is used to treat depression and to treat the combination of symptoms of anxiety and depression. Like most antidepressants, trazodone has also been used in limited numbers of patients to treat panic disorder, obsessive-compulsive disorder, attention-deficit/hyperactivity disorder, enuresis (bed-wetting), eating disorders such as bulimia nervosa, cocaine dependency, and the depressive phase of bipolar (manic-depressive) disorder. It should be noted, however, that trazodone has not received official approval from the United States Food and Drug Administration (FDA) for these secondary uses.

Trazodone hydrochloride is an antidepressant chemically unrelated to tricyclic, tetracyclic, or other known antidepressant agents. Trazodone hydrochloride is a triazolopyridine derivative designated as 2-[3-[4-(3-chlorophenyl)-1-piperazinyl] propyl]-1,2,4-triazolo[4,3-a]pyridin-3 (2H)-one hydrochloride. It is a white odorless crystalline powder which is freely soluble in water.

This report covers Trazodone Hydrochloride (API) (CAS Number: 25332-39-2) and Trazodone API (CAS Number: 19794-93-5).

Due to the COVID-19 pandemic, the global Trazodone Hydrochloride (API) market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Trazodone Hydrochloride (API) market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Trazodone Hydrochloride (API) landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.

Trazodone hydrochloride (API) consumed in USA are mostly imported from overseas. Major companies are Angelini, Mylan, SST Corporation, The Piramal Group. The sales market share of the four companies has reached 53%. The local factory, Teva occupied about 40% market share.

This report focuses on Trazodone Hydrochloride (API) volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Trazodone Hydrochloride (API) market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.

Global Trazodone Hydrochloride (API) Market: Segment Analysis

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.



Segment by Type


Trazodone Hydrochloride (API)

Others



Segment by Application


Antidepression

Anxiolytic

Hypnotic

Others


By Region

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Philippines

Vietnam

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

U.A.E



By Company


Teva

Angelini

Mylan

Fermion

The Piramal Group